|
|
Blood, 1 January 2004, Vol. 103, No. 1, pp. 236-241.
Prepublished online as a Blood First Edition Paper on September 4, 2003; DOI 10.1182/blood-2002-05-1352.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL
Takeshi Tsuchiya,
Koichi Ohshima,
Kennosuke Karube,
Takahiro Yamaguchi,
Hiroaki Suefuji,
Makoto Hamasaki,
Chika Kawasaki,
Junji Suzumiya,
Masao Tomonaga, and
Masahiro Kikuchi
From the Departments of Pathology and Internal Medicine, School of Medicine, Fukuoka University, Japan; and Department of Hematology, Atomic Disease Institute, Nagasaki University School of Medicine, Japan.
A new World Health Organization classification was recently proposed. However, classification of peripheral T-cell lymphomas remains to be clarified. Particularly, unspecified type was considered as a heterogeneous category. Here we studied the expressions of chemokine receptors, Th1-associated CXCR3 and CCR5 and Th2-associated marker ST2(L), and activated T-cell receptor OX40/CD134 in 185 patients with nodal T-cell lymphoma, and evaluated the relationship to prognosis. Their expression patterns correlated with the specific subtype of nodal T-cell lymphoma, such as angioimmunoblastic T-cell lymphoma (AILD), anaplastic large cell lymphoma (ALCL), and in peripheral T-cell lymphoma (PTCL), unspecified. In AILD, almost all cases were immunoreactive for OX40/CD134 (96%) and for CXCR3 (89%). In ALCL, all cases were immunonegative for OX40/CD134, and only a few cases (24%) were immunoreactive for CXCR3, whereas almost all cases (94%) were positive for ST2(L). Cases of PTCL, unspecified, were divided into 2 groups; group 1 (cases positive for either ST2(L), CCR5, or CXCR3) tended to show favorable prognosis compared with group 2 (cases negative for ST2(L), CCR5, and CXCR3). Our results indicate that further subtyping of PTCL, unspecified, into groups 1 and 2 could be significant for evaluating prognosis and understanding the functional role of these tumors.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Nakagawa, A. Nakagawa-Oshiro, S. Karnan, H. Tagawa, A. Utsunomiya, S. Nakamura, I. Takeuchi, K. Ohshima, and M. Seto
Array Comparative Genomic Hybridization Analysis of PTCL-U Reveals a Distinct Subgroup with Genetic Alterations Similar to Lymphoma-Type Adult T-Cell Leukemia/Lymphoma
Clin. Cancer Res.,
January 1, 2009;
15(1):
30 - 38.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mercadal, J. Briones, B. Xicoy, C. Pedro, L. Escoda, C. Estany, M. Camos, L. Colomo, I. Espinosa, S. Martinez, et al.
Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma
Ann. Onc.,
May 1, 2008;
19(5):
958 - 963.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Shimizu, A. Matsuda, K. Yanagisawa, T. Hirota, M. Akahoshi, N. Inomata, K. Ebe, K. Tanaka, H. Sugiura, K. Nakashima, et al.
Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis
Hum. Mol. Genet.,
October 1, 2005;
14(19):
2919 - 2927.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-Y. Au, S.-Y. Ma, C.-S. Chim, C. Choy, F. Loong, A. K. W. Lie, C. C. K. Lam, A. Y. H. Leung, E. Tse, C.-C. Yau, et al.
Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years
Ann. Onc.,
February 1, 2005;
16(2):
206 - 214.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Savage
Aggressive Peripheral T-Cell Lymphomas (Specified and Unspecified Types)
Hematology,
January 1, 2005;
2005(1):
267 - 277.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Savage, M. Chhanabhai, R. D. Gascoyne, and J. M. Connors
Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification
Ann. Onc.,
October 1, 2004;
15(10):
1467 - 1475.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ishida, H. Inagaki, A. Utsunomiya, Y. Takatsuka, H. Komatsu, S. Iida, G. Takeuchi, T. Eimoto, S. Nakamura, and R. Ueda
CXC Chemokine Receptor 3 and CC Chemokine Receptor 4 Expression in T-Cell and NK-Cell Lymphomas with Special Reference to Clinicopathological Significance for Peripheral T-Cell Lymphoma, Unspecified
Clin. Cancer Res.,
August 15, 2004;
10(16):
5494 - 5500.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
